SV7 Impact Medicine Fund LP - Oct 26, 2021 Form 4/A - Amendment Insider Report for Xilio Therapeutics, Inc. (XLO)

Role: 10%+ Owner
Signature: /s/ Kathleen R. Henry, pursuant to Power of Attorney for SV7 Impact Medicine Fund LP
Stock symbol: XLO
Transactions as of: Oct 26, 2021
Transactions value $: $10,000,000
Form type: 4/A - Amendment
Date filed: 11/3/2021, 04:20 PM
Date Of Original Report: Oct 28, 2021
Previous filing: Oct 21, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XLO	Common Stock	Conversion of derivative security		+999K			999K	Oct 26, 2021	Direct	F1, F2
transaction	XLO	Common Stock	Conversion of derivative security		+999K			999K	Oct 26, 2021	See footnote	F1, F2, F3
transaction	XLO	Common Stock	Conversion of derivative security		+303K	+30.3%		1.3M	Oct 26, 2021	Direct	F1, F2
transaction	XLO	Common Stock	Conversion of derivative security		+303K	+30.3%		1.3M	Oct 26, 2021	See footnote	F1, F2, F3
transaction	XLO	Common Stock	Purchase	$5M	+313K	+24.02%	$16.00^*	1.61M	Oct 26, 2021	Direct	F4
transaction	XLO	Common Stock	Purchase	$5M	+313K	+24.02%	$16.00^*	1.61M	Oct 26, 2021	See footnote	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XLO	Series B Convertible Preferred Stock	Conversion of derivative security	$0	-9.49M	-100%	$0.00^*	0	Oct 26, 2021	Common Stock	999K		Direct	F1
transaction	XLO	Series B Convertible Preferred Stock	Conversion of derivative security	$0	-9.49M	-100%	$0.00^*	0	Oct 26, 2021	Common Stock	999K		See footnote	F1, F3
transaction	XLO	Series C Convertible Preferred Stock	Conversion of derivative security	$0	-2.87M	-100%	$0.00^*	0	Oct 26, 2021	Common Stock	303K		Direct	F1
transaction	XLO	Series C Convertible Preferred Stock	Conversion of derivative security	$0	-2.87M	-100%	$0.00^*	0	Oct 26, 2021	Common Stock	303K		See footnote	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

SV7 Impact Medicine Fund LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date.
F2	Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021.
F3	Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom.
F4	This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering.